Study S001647

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder: a Pilot Mechanistic Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07227948
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 75
Start: 2026-01-15
Primary completion: 2029-01-28
Lead sponsor: The University of Texas Health Science Center, Houston
Conditions: Cocaine Use Disorder
Interventions: DRUG:Semaglutide; DRUG:Placebo; BEHAVIORAL:cognitive behavioral therapy (CBT).
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: NIH:R01DA062720-01

Registered primary outcomes

Amplitude of the Late Positive Potential (LPP) in microvolts in response to visual stimuli on the Picture Viewing Task. [End of Treatment (Week 15)]
Intensity of demand as assessed by the amount of cocaine purchased and consumed as assessed by cocaine purchasing task [End of Treatment (Week 15)]
Cocaine craving as assessed by the score on the Cocaine Cravings Questionnaire [End of Treatment (Week 15)]
Proportion of cocaine negative urine drug screens (UDS) during the final two weeks of treatment [From Week 13 to Week 14]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0003430	Repurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial. Yammine L, BMJ open	2026	Protocol	PMID 42161545 DOI	cites ClinicalTrials.gov:NCT07227948; registry reference DERIVED:42161545